IDH2 and central nervous system cancer: Therefore, R172K is expected to affect enzyme activity; the IDH2 variants are less common, with R172K observed in 3% of glioma patients, and detection of the R172K variant has implications for glioma diagnosis, prognosis, and potential treatment [55].